Not Yet RecruitingPhase 1

Magnetic Sentinel Lymph Node Mapping in Gastric Cancer

United States20 participantsStarted 2026-03-31

Plain-language summary

This phase I finds out the possible benefits and/or side effects of using magnetic tracer FerroTrace and the fluorescent dye indocyanine green to identify the lymph nodes that cancer is most likely to have spread to in patients with gastric cancer that are undergoing gastrectomy. Using FerroTrace in combination with the indocyanine green dye may help researchers better detect the disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 or older * Willing to provide informed consent * Biopsy proven gastric cancer, undergoing curative-intent gastrectomy * No distant metastases * Pathologic diagnosis of gastric adenocarcinoma * Pre-treatment endoscopic measurement of less than or equal to 4 cm in diameter of the gastric cancer Exclusion Criteria: * Contraindications to surgery +/- adjuvant therapy * Allergy or intolerance to iron oxide compounds * Allergy or intolerance to iodides * Iron overload disorder * Pregnant or lactating women\* * Use of contraception is required for females during the study. Male patients who are sexually active with a female of childbearing potential are allowed for study enrollment and will not require use of contraception

What they're measuring

Safety of endoscopic peritumoral gastric injection of FerroTrace

Timeframe: Within 24 hours of the FerroTrace injection

Trial details

NCT IDNCT05038098

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-02-02

Contact for this trial

Naruhiko Ikoma, MD

832-729-2675 nikoma@mdanderson.org

View on ClinicalTrials.gov More Gastric Adenocarcinoma trials